Table 3. Annualized direct and indirect costs relating to patients at the anticoagulation clinic who were using warfarin (n = 633).

All costs are in US dollars. INR = international normalized ratio. *The costs over the same period for a patient using the new oral anticoagulants would be: $ 598.44 for apixaban, $ 616.80 for dabigatran and $ 625.92 for rivaroxaban; ^†When the data from the study follow up is annualized, each patient would undergo 28 INR examinations on average.